Diagnosing TB in the Immunocompromised: What’s New?

Join Dr Roy Chemaly as he discusses effective TB testing methods in the immunocompromised population.
By the end of this webinar, you will understand the following:

• Differences between the three TB testing methods
• Importance of having a good or optimal test, and how the suboptimal test may affect outcome in patients
• TB test options for the immunocompromised patient population and which test works best
• Clinical utility of interferon-gamma release assays (IGRAs) in immunocompromised patient populations

Dr Roy F. Chemaly, MD, MPH, FIDSA, FACP Dr Roy Chemaly is a Professor of Medicine in the Department of Infectious Diseases, Infection Control & Employee Health at The University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Chemaly is the Director of the Infection Control and the Antimicrobial Stewardship programs at MD Anderson Cancer Center. He heads the Viral Protection Ad Hoc Infection Control Subcommittee, and serves as Director of the Clinical Virology Research Program in the Department of Infectious Diseases.